Shigemi S Matsuyama

US Patent:

8183342, May 22, 2012

Filed:

Nov 6, 2008

Appl. No.:

12/266244

Inventors:

Shigemi Matsuyama - Beachwood OH, US

Assignee:

Case Western Reserve University - Cleveland OH

International Classification:

C07K 5/10

US Classification:

530330, 514 218, 514 137, 514 219

Abstract:

A method of treating chemotherapy-induced thrombocytopenia includes administering to a subject undergoing chemotherapy a therapeutically effective amount of a Bax-inhibiting peptide.

US Patent:

8324170, Dec 4, 2012

Filed:

Aug 9, 2010

Appl. No.:

12/853122

Inventors:

Shigemi Matsuyama - Beachwood OH, US

Assignee:

Case Western Reserve University - Cleveland OH

International Classification:

A61K 38/08
A61K 38/04
A61K 38/16
C07K 14/715

US Classification:

514 189, 514 213, 514 214, 514 215, 514 216, 514 217, 514 218

Abstract:

A method of inhibiting apoptosis in a cell includes administering to a cell an effective amount of a cell penetrating peptide (CPP), wherein the CPP consists of about 5 to about 41 amino acids and is substantially homologous to a portion of the C-terminal region of IFNγR2.

US Patent:

20030073661, Apr 17, 2003

Filed:

Sep 19, 2002

Appl. No.:

10/247045

Inventors:

Shigemi Matsuyama - Glendale WI, US
Weiyong Sun - Kawasaki City, JP

International Classification:

A61K048/00
C12Q001/68
G01N033/574

US Classification:

514/044000, 435/006000, 435/007230, 424/093200

Abstract:

A method of predicting whether cells would respond to therapies which are mediated through Bax-regulated apoptosis is disclosed. In one embodiment, the method comprises the step of: (a) examining the intensity of the expression of the Bax protein or mRNA in a cell relative to a control, and (b) based on that intensity level, predicting whether cells will respond to therapies which are mediated through Bax-regulated apoptosis, wherein a high Bax level indicates that one may lower Ku70 levels and increase sensitivity to apoptosis. In another embodiment, the invention is a method of sensitizing cells to cancer therapy, comprising the step of reducing the cell's native Ku70 protein level. In another embodiment the invention is method of treating cell death-related diseases comprising the step of increasing cellular Ku70 protein level.

US Patent:

20030216323, Nov 20, 2003

Filed:

Feb 28, 2003

Appl. No.:

10/375980

Inventors:

Shigemi Matsuyama - Glendale WI, US

International Classification:

A61K038/08
A61K038/06

US Classification:

514/017000, 514/018000

Abstract:

A method of protecting cells from cell death comprising the step of supplying to the cell an effective amount of a Bax-inhibiting peptide is disclosed.

US Patent:

20050026201, Feb 3, 2005

Filed:

Aug 23, 2004

Appl. No.:

10/924060

Inventors:

Shigemi Matsuyama - Glendale WI, US
Weiyong Sun - Kawasaki City, JP

International Classification:

C12Q001/68
G01N033/53
G01N033/567
G01N033/574

US Classification:

435006000, 435007230

Abstract:

A method of predicting whether cells would respond to therapies which are mediated through Bax-regulated apoptosis is disclosed. In one embodiment, the method comprises the step of: (a) examining the intensity of the expression of the Bax protein or mRNA in a cell relative to a control, and (b) based on that intensity level, predicting whether cells will respond to therapies which are mediated through Bax-regulated apoptosis, wherein a high Bax level indicates that one may lower Ku70 levels and increase sensitivity to apoptosis. In another embodiment, the invention is a method of sensitizing cells to cancer therapy, comprising the step of reducing the cell's native Ku70 protein level. In another embodiment the invention is method of treating cell death-related diseases comprising the step of increasing cellular Ku70 protein level.

US Patent:

20070036775, Feb 15, 2007

Filed:

Oct 13, 2006

Appl. No.:

11/580478

Inventors:

Shigemi Matsuyama - Glendale WI, US
Weiyong Sun - Kawasaki City, JP

International Classification:

A61K 48/00
C12Q 1/68

US Classification:

424093210, 435006000

Abstract:

A method of predicting whether cells would respond to therapies which are mediated through Bax-regulated apoptosis is disclosed. In one embodiment, the method comprises the step of: (a) examining the intensity of the expression of the Bax protein or mRNA in a cell relative to a control, and (b) based on that intensity level, predicting whether cells will respond to therapies which are mediated through Bax-regulated apoptosis, wherein a high Bax level indicates that one may lower Ku70 levels and increase sensitivity to apoptosis. In another embodiment, the invention is a method of sensitizing cells to cancer therapy, comprising the step of reducing the cell's native Ku70 protein level. In another embodiment the invention is method of treating cell death-related diseases comprising the step of increasing cellular Ku70 protein level.

US Patent:

20080096824, Apr 24, 2008

Filed:

Sep 27, 2007

Appl. No.:

11/862504

Inventors:

Shigemi Matsuyama - Glendale WI, US

International Classification:

A61K 38/00
A61P 9/00
C12N 5/06

US Classification:

514017000, 435375000

Abstract:

A method of protecting cells from cell death comprising the step of supplying to the cell an effective amount of a Bax-inhibiting peptide is disclosed.

US Patent:

20080103101, May 1, 2008

Filed:

Sep 27, 2007

Appl. No.:

11/862560

Inventors:

Shigemi Matsuyama - Glendale WI, US

International Classification:

A61K 38/00
A61P 43/00
C12N 5/06

US Classification:

514017000, 435375000, 514018000

Abstract:

A method of protecting cells from cell death comprising the step of supplying to the cell an effective amount of a Bax-inhibiting peptide is disclosed.